|
시장보고서
상품코드
2008125
플루마제닐 시장 : 투여량별, 용도별, 유통 채널별, 지역별Flumazenil Market, By Dose, By Application, By Distribution Channel, By Geography |
||||||
플루마제닐 시장은 2026년에 2,170만 달러로 추정되며, 2033년까지 2,880만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 6.2%로 성장할 것으로 전망됩니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 2,170만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) | 6.20% | 예측 금액(2033년) | 2,880만 달러 |
플루마제닐은 벤조디아제핀 길항제입니다. 플루마제닐은 벤조디아제핀계 마취제에 의한 수술 후 진정을 위한 해독제로 사용됩니다. 플루마제닐 주사제는 성인과 소아의 의식하 진정 및 전신 마취에서 벤조디아제핀의 진정 작용을 완전히 또는 부분적으로 해제하기 위해 권장됩니다.
플루마제닐은 성인의 벤조디아제핀 과다 복용 관리 및 치료에도 적응증을 가지고 있습니다. 벤조디아제핀 과다 복용으로 인한 혼수상태를 해제하는 데 사용됩니다. 플루마제닐은 다약제 과다복용 환자보다 벤조디아제핀 중독으로 인한 혼수상태를 해제하는 데 더 효과적입니다.
시장 역학
플루마제닐을 이용한 혼수상태 치료에 대한 연구 개발의 증가는 세계 플루마제닐 시장의 성장을 촉진할 것으로 예상됩니다. 예를 들어, 2021년 5월 9일 Journal of Medical Case Reports에 게재된 연구 데이터에 따르면, 연구진은 글래스고 코마 척도(GCS)가 15명의 환자에서 플루마제닐이 신경인지 기능의 완전한 회복에 좋은 결과를 보였다고 보고했습니다. GCS가 3으로 반응하지 않는 환자에게는 0.25 mg의 플루마제닐을 정맥으로 투여했습니다. 플루마제닐 투여 후 환자는 신경인지기능이 완전히 회복되었습니다.
예측 기간 동안 졸음 문제에 직면하는 사람들의 증가는 세계 플루마제닐 시장의 성장을 견인할 것으로 예상됩니다. 예를 들어, 유럽운수노동자연맹이 발표한 자료에 따르면, 2019년 런던에서 실시된 조사에서 1,353명의 버스 운전사 중 37%가 졸음과 싸우며 깨어있어야 하는 것으로 보고되었습니다. 플루마제닐은 졸음으로 고생하는 환자의 치료에 사용됩니다. 정맥으로 투여되는 플루마제닐 주사는 졸음에 직면한 사람들의 치료에 더 효과적입니다.
본 보고서의 주요 특징
- 세계의 플루마제닐 시장에 대해 조사 분석했으며, 2021년을 기준 연도로 하여 예측 기간(2022-2030년)의 시장 규모와 연평균 성장률(CAGR)을 조사 분석하여 전해드립니다.
- 또한, 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한, 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요한 인사이트를 제공합니다.
- 이 보고서는 회사 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등의 매개 변수를 기반으로 세계 플루마제닐(Flumazenyl) 시장의 주요 기업 프로파일을 제공합니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 종류 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- "세계 플루마제닐 시장" 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 플루마제닐 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 플루마제닐 시장 : 투여량별(2026-2033년)
제5장 세계의 플루마제닐 시장 : 용도별(2026-2033년)
제6장 세계의 플루마제닐 시장 : 유통 채널별(2026-2033년)
제7장 세계의 플루마제닐 시장 : 지역별(2026-2033년)
제8장 경쟁 구도
제9장 섹션
KSMFlumazenil Market is estimated to be valued at USD 21.7 Mn in 2026 and is expected to reach USD 28.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 6.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 21.7 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.20% | 2033 Value Projection: | USD 28.8 Mn |
Flumazenil is a benzodiazepine inhibitor Flumazenil are used as reversal drug for postsurgical sedation from benzodiazepine anesthetics. Flumazenil injection is recommended for a complete or partial reversal of the sedative effects of benzodiazepines in conscious sedation and general anesthesia in adult and pediatric populations.
Flumazenil is also designated for the management and treatment of benzodiazepine overdose in adults. It is used in reversing coma due to benzodiazepine overdose. Flumazenil is more effective in reversing coma in benzodiazepine intoxication than patients with multiple drug overdoses.
Market Dynamics
Increasing research and development for the treatment of coma using flumazenil is expected to propel growth of the global flumazenil market. For instance, according to research data published on May 9, 2021, in Journal of Medical Case Reports, researchers have reported that flumazenil has showed positive result in complete neurocognitive recovery of patient with a Glasgow Coma Score of 15. 0.25 mg of flumazenil was intravenously administered to the patient who was unresponsive with Glass Coma Score of 3. After the patient was directed with flumazenil, the patient completely recovered by neurocognitive.
Increasing cases of people facing drowsiness problem is expected to drive growth of the global flumazenil market, over the forecast period. For instance, according to data published by European Transport Workers' Federation, in 2019 a survey done in city of London, reported that among 1353 bus drivers 37% of the drivers had to fight with drowsiness in order to stay awake. Flumazenil is used for the treatment of patients suffering from drowsiness. Flumazenil injections given through vein are more effective to treat people facing drowsiness.
Key features of the study
- This report provides an in-depth analysis of the global flumazenil market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global flumazenil market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Hoffmann La Roche, Akorn-Strides, LLC, Sandoz Canada Incorporated, Fresenius Kabi USA, LLC, Mylan Pharmaceuticals, Genentech, Inc., General Injectables & Vaccines Inc, Sina Health Inc, West Ward Pharmaceutical, HF Acquisition Co. LLC, DBA HealthFirst, Hikma Farmaceutica, Pfizer Laboratories Div Pfizer Inc., Physicians Total Care, Inc., and Bedford Pharmaceuticals
- Insights from this report would allow marketers and management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global flumazenil market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global flumazenil market.
Market Segmentation
- By Dose
- 5 ml
- 10 ml
- By Application
- Anti - Sedation
- Reversing Drowsiness
- Others (Hepatic Encephalopathy, Cirrhosis)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Regional Insights
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Hoffmann La Roche
- Akorn-Strides, LLC
- Sandoz Canada Incorporated
- Fresenius Kabi USA, LLC
- Mylan Pharmaceuticals
- Genentech, Inc.
- General Injectables & Vaccines Inc
- Sina Health Inc
- West Ward Pharmaceutical
- HF Acquisition Co. LLC
- DBA HealthFirst
- Hikma Farmaceutica
- Pfizer Laboratories Div Pfizer Inc.
- Physicians Total Care, Inc.
- Bedford Pharmaceuticals.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Dose
- Market Snippet, By Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Regulatory Scenario
- PEST Analysis
- Recent Product Launch/Approval
- Epidemiology
- Mergers and Acquisitions
4. Global Flumazenil Market, By Dose, 2026-2033 (USD Million)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- 5 ml
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- 10 ml
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
5. Global Flumazenil Market, By Application, 2026 - 2033 (USD Million)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Anti - Sedation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Reversing Drowsiness
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Others (Hepatic Encephalopathy, Cirrhosis)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
6. Global Flumazenil Market, By Distribution Channel, 2026 - 2033 (USD Million)
- Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
7. Global Flumazenil Market, By Region, 2026 - 2033 (USD Million)
- Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2033
- Regional Trends
- North America
- Market Size and Forecast, By Dose, 2026-2033 (USD Mn)
- Market Size and Forecast, By Application, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Dose, 2026-2033 (USD Mn)
- Market Size and Forecast, By Application, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Dose, 2026-2033 (USD Mn)
- Market Size and Forecast, By Application, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Dose, 2026-2033 (USD Mn)
- Market Size and Forecast, By Application, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Dose, 2026-2033 (USD Mn)
- Market Size and Forecast, By Application, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Dose, 2026-2033 (USD Mn)
- Market Size and Forecast, By Application, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
- South Africa
- Central Africa
- North Africa
8. Competitive Landscape
- Company Profiles
- Hoffmann La Roche
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Akorn-Strides, LLC
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Sandoz Canada Incorporated
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Fresenius Kabi USA, LLC
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Mylan Pharmaceuticals
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Genentech, Inc.
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- General Injectables & Vaccines Inc
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Sina Health Inc.
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- West Ward Pharmaceutical
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- HF Acquisition Co. LLC, DBA HealthFirst
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Hikma Farmaceutica
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Pfizer Laboratories Div Pfizer Inc.
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Physicians Total Care, Inc.
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Bedford Pharmaceuticals
- Company Overview
- Drug Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Analyst Views
- Hoffmann La Roche
9. Section
- References
- Research Methodology
- About us and Sales Contact
